Stockreport

Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026

Longeveron Inc. - Class A Common stock  (LGVN) 
PDF MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare [Read more]